COMP <GO>
CI vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
The Cigna Group (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CI 5
— JNJ 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $298.23 (-0.06%) • MKT CAP: $78.85B
balance-sheet
2.70
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CI VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CI | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 21.80% | 67.90% | -46.10 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.80% | 25.50% | -16.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | 18.5x | -12.40 | CI | /valuation <GO> |
| Free Cash Flow Yield | -3.51% | 2.97% | -6.48 | JNJ | /fcf-yield <GO> |
| Operating Margin | 3.30% | 34.70% | -31.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 2.20% | 28.50% | -26.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 6.00% | +5.20 | CI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.04% | 0.00% | +2.04 | CI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.70 | 5.59 | -2.89 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.20% | +0.10 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.6 | 60.4 | -4.73 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 1.08 | +0.04 | CI | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.3x | 23.0x | -10.70 | CI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $78.85B | $662.49B | -$583.64B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CI REV | JNJ REV | CI GROSS % | JNJ GROSS % | CI FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $274.90B | $94.19B | 21.8% | 67.9% | -$2.77B | $19.70B |
| FY 2024 | $247.12B | $88.82B | 26.1% | 69.1% | -$757.4M | $19.84B |
| FY 2023 | $195.26B | $85.16B | 44.0% | 44.0% | $3.03B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CI // BETA 1.12
JNJ // BETA 1.08